The 4th Process Development for Cell Therapies Summit- What's It About?
If you’re a technical leader working in process development—this meeting is for YOU.
Join us to streamline your cell therapy development and manufacturing processes at this must-attend event for the cell therapy field, uniting experts across process development, technical operations, QC, AD, CMC, MSAT, and beyond. Our mission: driving the production of safe, effective, and consistent autologous and allogeneic cell therapies.
What's New for 2025?
In response to industry feedback, this year's summit will feature specialized workshops tailored to both early and late-stage process development challenges. Gain targeted insights to optimize scalability, reproducibility, and product quality.
Explore the latest automation solutions—from qualification to drug product application—to enhance efficiency and reduce variability.
Plus, take advantage of a dedicated poster session to showcase your work and receive valuable feedback from peers tackling the same challenges. Don’t miss the chance to engage with the brightest minds in cell therapy—submit your poster today!
4 Process-Perfecting Insights You Can't Afford to Miss:
Accelerate scale-up and commercialization of cell therapies by optimizing process development, navigating regulatory challenges, and collaborating effectively with CDMOs to ensure consistent quality and efficient tech transfer with Tenpoint Therapeutics, Johnson & Johnson, Arsenal Bio & BMS
Enhance product consistency and quality with optimized CQAs and control strategies alongside Cabaletta Bio, Immatics, Genetech, Cellectis & more by employing high-throughput analytics, streamlining raw material management, optimizing cryopreservation profiles and addressing donor variability across autologous and allogeneic therapies
Leverage automation, AI, and advanced analytics to drive manufacturing efficiency by integrating real-time data collection, automating workflows, and improving predictive insights to reduce costs and accelerate production timelines with Galapagos, Artiva Biotherapeutics, Lyell Pharma & Takeda
Ensure process comparability and regulatory alignment by establishing robust early-stage foundations, and hear from Immatics, Takeda, and BioNTech on managing process changes in late-stage development, and balancing standardization with customization across diverse indications.
Who Will You Meet?
Connect with industry leaders, decision-makers, technical experts, and leading solution providers committed to advancing the PD space. This diverse group includes innovators shaping both early and late-stage process development, automation solutions, and the manufacturing of autologous and allogeneic cell therapies.
If you’d like more details on the 2025 summit’s audience breakdown and companies in the room, feel free to schedule an event consultation with the team here.
What Your Peers Have to Say:
“The niche focus made all the talks highly relevant, and the speakers were excellent.”
– 2025 Speaker, Associate Director, Inceptor Bio
“The narrow scope and intimate setting made it easy to have meaningful conversations with everyone.”
– 2024 Attendee, Scientist, Vor Bio
“The intimate nature of the meeting created an environment where conversations flowed naturally. The talks were high-quality and focused, adding real value.”
– 2024 Attendee, Senior Director, Neogene Therapeutics